Web Content Display

Tadalafil (Cialis) is one of the most popular erectile dysfunction (ED) drugs. The drug comes in low-dose versions that can be taken daily. This means you can have sex at any time, rather than needing to take a pill from time to time as needed like other ED brands. The starting dose for daily-use Cialis is 2.5 milligrams (mg). If that doesn't work, you can increase your daily dose up to 5 mg. But is this the right approach for you—or are you better off with traditional ED drugs like Viagra, Levitra, or even the nondaily version of Cialis? If you are contemplating Cialis for daily use, consider these questions and then discuss it with your doctor: If it's two or more times a week, a daily pill might be a reasonable choice, since the drug continually circulates in your bloodstream. A daily pill clears the path for sex at any time—if the drug works for you. (Remember, just like other ED drugs, it may not work for everyone).

Drug Class	Interaction Effect	Notes
Nitrates	Severe hypotension	Contraindicated
Alpha-blockers	Additive blood pressure lowering	Use caution, monitor BP
CYP3A4 inhibitors	Increased tadalafil levels	Dose adjustment may be needed
Antibiotics (e.g., erythromycin)	Potential increased levels	Monitor for side effects
Other PDE5 inhibitors	Possible additive effects	Do not combine

On the other hand, the 36-hour window offered by the nondaily version of Cialis might offer enough spontaneity. Have side effects of your current ED pill been bothering you? Taking a daily low-dose pill may reduce tadalafil in women side effects, though it may reduce effectiveness as well. In studies, the most common daily pill side effects were headache, muscle pain, indigestion, and back pain.

Property	Description	Value/Notes
Active Ingredient	Tadalafil	5 mg
Drug Class	Phosphodiesterase type 5 inhibitor	-
Half-life	17.5 hours	Approximate
Bioavailability	~80%	Oral administration
Absorption Time	2 hours	Peak plasma concentration
Metabolism	Liver (via CYP3A4 enzyme)	-
Excretion	Feces (~61%), Urine (~36%)	-

Men taking Cialis for daily use can experience a worrisome drop in blood pressure if they drink too much. Ask your doctor if any medications or supplements you take might interact with a daily erectile dysfunction pill, including blood pressure drugs, antifungal drugs, and HIV drugs. Also, men taking nitrate medications are advised not to take any ED drugs. While the manufacturer suggests that a 30-day supply of daily Cialis should cost about the same as eight pills of 36-hour Cialis a month, there's no way to enforce this. Check your insurance policy and local pharmacies for price information. – By Matthew Solan Executive Editor, Harvard Men's Health Watch As a service to our readers, Harvard Health Publishing provides access to our library of archived content.

Aspect	Details
Recommended Dose	5 mg once daily
Timing of Dose	With or without food, same time daily
Missed Dose	Take as soon as remembered, do not double dose
Duration of Use	As prescribed, typically long-term
Overdose	Seek medical attention; symptoms may include headache, dizziness

Please note the date of last review or update on all articles. No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician.

5.1 Cardiovascular

Also, men taking nitrate medications are advised not to take any ED drugs. While the manufacturer suggests that a 30-day supply of daily Cialis should cost about the same as eight pills of 36-hour Cialis a month, there's no way to enforce this. Check your insurance policy and local pharmacies for price information. – By Matthew Solan Executive Editor, Harvard Men's Health Watch As a service to our readers, Harvard Health Publishing provides access to our library of archived content. Please note the date of last review or update on all articles.

News Abdi İbrahim Extends its Healing Touch to the Gulf

No content on this site, regardless of date, should ever be used as a substitute for direct medical advice from your doctor or other qualified clinician. Get the latest in health news delivered to your inbox! To explore the impact of patient-characteristics and relevant comorbidities on treatment continuation rates, effectiveness, and satisfaction in patients with erectile dysfunction (ED) who started or switched to tadalafil 5 mg once daily (TAD-OaD) at baseline. In the EDATE observational study, phosphodiesterase-type-5 (PDE5)-inhibitor pretreated or naïve ED patients who started or switched to TAD-OaD were prospectively followed for 6 months. Time to discontinuation of TAD-OaD was estimated using the Kaplan-Meier product-limit method at Months 2, 4, and 6 in subgroups stratified by age (18 − 65 years and >65 years), PDE5-inhibitor pretreatment, ED-severity (mild, moderate, severe), and presence or absence of relevant comorbidities (BPH, diabetes, CVD, hypertension, dyslipidemia).

Comparison with actions of other PDE5 inhibitors

LSmean change from baseline in International Index of Erectile Function (IIEF) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores and associated 95 % CIs were assessed using a mixed-model for repeated measures. Visit, ED etiology, and subgroups were included as fixed-effects. Overall, 778 patients received prescriptions for initiating or switching to TAD-OaD at baseline. At Month 2, >90 % of patients remained on TAD-OaD, except those aged >65 years (86.7 %) and patients with severe ED (89.0 %). More than 80 % of patients in all subgroups, except those aged >65 years (75.0 %), continued TAD-OaD at Month 6. Get the latest in health news delivered to your inbox! To explore the impact of patient-characteristics and relevant comorbidities on treatment continuation rates, effectiveness, and satisfaction in patients with erectile dysfunction (ED) who started or switched to tadalafil 5 mg once daily (TAD-OaD) at baseline. In the EDATE observational study, phosphodiesterase-type-5 (PDE5)-inhibitor pretreated or naïve ED patients who started or switched to TAD-OaD were prospectively followed for 6 months.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	10mg	60 + 6 Pills	105.81€ 100.77€	Buy
Cialis Generic	2.5mg	270 + 10 Pills	199.64€ 190.13€	Buy
Cialis Generic	10mg	120 + 6 Pills	178.49€ 169.99€	Buy
Cialis Generic	40mg	270 + 10 Pills	382.19€ 363.99€	Buy
Cialis Generic	40mg	360 + 10 Pills	477.87€ 455.11€	Buy
Cialis Generic	10mg	10 Pills	31.41€ 29.91€	Buy
Cialis Generic	2.5mg	10 Pills	28.51€ 27.15€	Buy
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€	Buy
Cialis Generic	5mg	20 Pills	41.99€ 39.99€	Buy
Cialis Generic	5mg	360 + 10 Pills	268.08€ 255.31€	Buy
Cialis Generic	20mg	20 Pills	54.72€ 52.11€	Buy
Cialis Generic	2.5mg	120 + 6 Pills	128.93€ 122.79€	Buy
Cialis Generic	5mg	10 Pills	29.39€ 27.99€	Buy
Cialis Generic	20mg	60 + 6 Pills	117.76€ 112.15€	Buy
Cialis Generic	40mg	60 + 6 Pills	130.98€ 124.74€	Buy
Cialis Generic	10mg	270 + 10 Pills	308.71€ 294.01€	Buy
Cialis Generic	60mg	360 + 10 Pills	570.52€ 543.35€	Buy

Time to discontinuation of TAD-OaD was estimated using the Kaplan-Meier product-limit method at Months 2, 4, and 6 in subgroups stratified by age (18 − 65 years and >65 years), PDE5-inhibitor pretreatment, ED-severity (mild, moderate, severe), and presence or absence of relevant comorbidities (BPH, diabetes, CVD, hypertension, dyslipidemia). LSmean change from baseline in International Index of Erectile Function (IIEF) and Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) scores and associated 95 % CIs were assessed using a mixed-model for repeated measures.

Shipping & Delivery

Tadalafil (Cialis) is one of the most popular erectile dysfunction (ED) drugs. The drug comes in low-dose versions that can be taken daily. This means you can have sex at any time, rather than needing to take a pill from time to time as needed like other ED brands. The starting dose for daily-use Cialis is 2.5 milligrams (mg). If that doesn't work, you can increase your daily dose up to 5 mg.

News Abdi İbrahim and GSK Türkiye Make Major Investment for Domestic Production of Respiratory Medicine

But is this the right approach for you—or are you better off with traditional ED drugs like Viagra, Levitra, or even the nondaily version of Cialis? If you are contemplating Cialis for daily use, consider these questions and then discuss it with your doctor: If it's two or more times a week, a daily pill might be a reasonable choice, since the drug continually circulates in your bloodstream. A daily pill clears the path for sex at any time—if the drug works for you. (Remember, just like other ED drugs, it may not work for everyone). On the other hand, the 36-hour window offered by the nondaily version of Cialis might offer enough spontaneity.

Trial Registration

Have side effects of your current ED pill been bothering you? Taking a daily low-dose pill may reduce tadalafil in women side effects, though it may reduce effectiveness as well. In studies, the most common daily pill side effects were headache, muscle pain, indigestion, and back pain. Men taking Cialis for daily use can experience a worrisome drop in blood pressure if they drink too much. Ask your doctor if any medications or supplements you take might interact with a daily erectile dysfunction pill, including blood pressure drugs, antifungal drugs, and HIV drugs. Visit, ED etiology, and subgroups were included as fixed-effects. Overall, 778 patients received prescriptions for initiating or switching to TAD-OaD at baseline. At Month 2, >90 % of patients remained on TAD-OaD, except those aged >65 years (86.7 %) and patients with severe ED (89.0 %).

• In rare cases, tadalafil can cause vision changes.
• Allergic reactions may include rash, swelling, or difficulty breathing.
• Seek medical advice if side effects are severe or persistent.

More than 80 % of patients in all subgroups, except those aged >65 years (75.0 %), continued TAD-OaD at Month 6. There was a significant LSmean negative effect on IIEF- EF domain-score improvement for BPH (LSmean effect [95 % CI]: −2.77 [−4.98, −0.55], p = 0.014), previous PDE5-inhibitor treatment (−2.13 [−3.33,-0.94], p < 0.001), and mild tadalafil pills vs moderate ED (-2.00 [−3.54,-0.46], p = 0.011); the latter possibly linked with a bigger treatment-effect in those with more severe ED at baseline. The LSmean effect on change in IIEF-EF was significantly positive for diabetes (2.28 [0.64,3.92], p = 0.007), most likely because those with diabetes had more severe ED at baseline. For all other parameters, no statistically significant LSmean effects in IIEF-EF changes were observed. No comorbidity or baseline-characteristic except age (18 − 65 years vs >65 years: 11.25 [2.96,19.54], p = 0.008) affected changes in EDITS.

• The medication can be taken with or without food.
• Common side effects include headache and flushing.
• Consult your doctor before starting tadalafil 5mg.

Under routine clinical conditions, treatment continuation rate or satisfaction does not seem to be significantly affected by the presence of comorbidities in men who choose ED-treatment with TAD-OaD. The magnitude of treatment effectiveness was affected by certain baseline characteristics and comorbid conditions. The study (H6D-EW-LVIU) is registered in the German VfA Registry of Non-Interventional Studies (Verband Forschender Arzneimittelhersteller) since 06 December 2011; available at: Men with erectile dysfunction (ED) have several comorbid conditions such as cardiovascular disease (CVD) and associated risk factors including diabetes, hypertension, dyslipidemia, smoking, obesity, sedentary lifestyle, and others such as depression, premature ejaculation, lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), and overactive bladder [1–4]. In the Men’s Attitudes to Life Events and Sexuality (MALES) study, 64 % of the men reported having at least 1 comorbid condition including hypertension (36 %), dyslipidemia (29 %), depression (25 %), CVD (17 %), and diabetes (14 %) [1].

5.5 Sudden Hearing Loss

In this article, we present results of secondary analyses for the impact of patient characteristics and relevant comorbidities on treatment continuation rates as well as treatment effectiveness and satisfaction in patients with ED who had started with or switched to tadalafil OaD and were followed for a period of 6 months. EDATE was a prospective, longitudinal, observational study conducted in 59 centres across Germany, France, Italy, and Greece, enrolling patients from November 2011 through June 2012 [20]. Adult male patients who met the investigator’s criteria for ED and presented within the normal course of care were eligible to participate if they had decided, in consultation with their physician, to either initiate PDE5 inhibitor treatment for the first time (treatment-naïve) or switch from any previous PDE5 inhibitor taken on-demand. Patients with previous experience with tadalafil OaD were excluded. The study was approved by the Comité de protection des personnes “Nord-Ouest IV”, centre hospitalier universitaire, tadalafil over the counter uk faculté de médecine, pôle recherche, 59045 Lille Cedex, and additional ethical review boards as per individual study site and country requirements (full list provided as Additional file 1).

Tadalafil may cause side effects. Tell your doctor if any of these symptoms are severe or do not go away:

Patients provided written informed consent for data collection, storage, and release of anonymised data. Assessment and treatment of patients were performed as per routine investigator practice for managing ED. In this article, data from patients who initiated or switched to treatment with tadalafil OaD at baseline (Visit 1) and were followed up longitudinally for up to 6 months (tadalafil OaD cohort) are reported. Post-baseline data were collected at routine visits (Visit 2, Visit 3) within 1 to 3 months and 4 to 6 months after initiation of therapy. Patients who switched or discontinued tadalafil OaD treatment during the observation were followed until the end of the 6-month observation period.

Additional file 6: (download PDF )

A follow-up phone call was made to patients who did not visit within 4 to 6 months after baseline. The primary results on the time to treatment discontinuation of tadalafil OaD in men who had initiated or switched to tadalafil OaD at baseline have already been published [20]. The current article includes secondary outcome results on the impact of patients characteristics and comorbidities on time to treatment discontinuation, and on mean changes from baseline to end of observation in the International Index of Erectile Function (IIEF) domain scores [21], and Erectile Dysfunction Inventory for Treatment Satisfaction (EDITS) total score [22]. A sample size of 250 patients initiating or switching to tadalafil OaD at baseline was planned, based on the primary outcome (continuation rate on tadalafil OaD, estimated to be 50 − 80 % after 6 months of treatment) [20]. Consecutive enrollment was planned to be stopped as soon as either 3,000 patients were enrolled overall, or 600 patients were enrolled in the tadalafil OaD cohort. Given these prevalence rates of comorbidities in men with ED, it is important to choose an appropriate treatment that maintains its efficacy and tolerability in the presence of the comorbidities [5]. Oral phosphodiesterase type 5 (PDE5) inhibitors including avanafil, sildenafil, tadalafil, and vardenafil are proven to be safe and effective for managing ED [6–14]. Furthermore, these drugs have demonstrated efficacy in men with ED who have comorbid cardiovascular risk factors including hypertension, dyslipidemia, and/or diabetes [5], and tadalafil once daily (OaD) has shown efficacy in the treatment of BPH/LUTS [15–17]. It has been suggested that appropriate treatment of concomitant ED may help in improving the adherence and management of associated comorbidities, which may eventually decrease healthcare costs and improve the overall health of the affected men [18]. However, some pharmacological drugs used for treating these comorbid conditions have sexual side effects. This further underscores the significance of choosing an efficacious medication for treating ED in these subpopulations, if required. The study highlighted that more than 85 % of men who choose to be treated with tadalafil OaD maintained the treatment in the next 6 months [20]. In this article, we present results of secondary analyses for the impact of patient characteristics and relevant comorbidities on treatment continuation rates as well as treatment effectiveness and satisfaction in patients with ED who had started with or switched to tadalafil OaD and were followed for a period of 6 months.

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

There was a significant LSmean negative effect on IIEF- EF domain-score improvement for BPH (LSmean effect [95 % CI]: −2.77 [−4.98, −0.55], p = 0.014), previous PDE5-inhibitor treatment (−2.13 [−3.33,-0.94], p < 0.001), and mild tadalafil pills vs moderate ED (-2.00 [−3.54,-0.46], p = 0.011); the latter possibly linked with a bigger treatment-effect in those with more severe ED at baseline. The LSmean effect on change in IIEF-EF was significantly positive for diabetes (2.28 [0.64,3.92], p = 0.007), most likely because those with diabetes had more severe ED at baseline. For all other parameters, no statistically significant LSmean effects in IIEF-EF changes were observed. No comorbidity or baseline-characteristic except age (18 − 65 years vs >65 years: 11.25 [2.96,19.54], p = 0.008) affected changes in EDITS. Under routine clinical conditions, treatment continuation rate or satisfaction does not seem to be significantly affected by the presence of comorbidities in men who choose ED-treatment with TAD-OaD.

Some side effects can be serious. If you experience any of these symptoms, call your doctor immediately or get emergency medical treatment:

The magnitude of treatment effectiveness was affected by certain baseline characteristics and comorbid conditions. The study (H6D-EW-LVIU) is registered in the German VfA Registry of Non-Interventional Studies (Verband Forschender Arzneimittelhersteller) since 06 December 2011; available at: Men with erectile dysfunction (ED) have several comorbid conditions such as cardiovascular disease (CVD) and associated risk factors including diabetes, hypertension, dyslipidemia, smoking, obesity, sedentary lifestyle, and others such as depression, premature ejaculation, lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), and overactive bladder [1–4]. In the Men’s Attitudes to Life Events and Sexuality (MALES) study, 64 % of the men reported having at least 1 comorbid condition including hypertension (36 %), dyslipidemia (29 %), depression (25 %), CVD (17 %), and diabetes (14 %) [1]. Given these prevalence rates of comorbidities in men with ED, it is important to choose an appropriate treatment that maintains its efficacy and tolerability in the presence of the comorbidities [5]. Oral phosphodiesterase type 5 (PDE5) inhibitors including avanafil, sildenafil, tadalafil, and vardenafil are proven to be safe and effective for managing ED [6–14].

Outcome measures

Furthermore, these drugs have demonstrated efficacy in men with ED who have comorbid cardiovascular risk factors including hypertension, dyslipidemia, and/or diabetes [5], and tadalafil once daily (OaD) has shown efficacy in the treatment of BPH/LUTS [15–17]. It has been suggested that appropriate treatment of concomitant ED may help in improving the adherence and management of associated comorbidities, which may eventually decrease healthcare costs and improve the overall health of the affected men [18]. However, some pharmacological drugs used for treating these comorbid conditions have sexual side effects. This further underscores the significance of choosing an efficacious medication for treating ED in these subpopulations, if required. The study highlighted that more than 85 % of men who choose to be treated with tadalafil OaD maintained the treatment in the next 6 months [20]. EDATE was a prospective, longitudinal, observational study conducted in 59 centres across Germany, France, Italy, and Greece, enrolling patients from November 2011 through June 2012 [20]. Adult male patients who met the investigator’s criteria for ED and presented within the normal course of care were eligible to participate if they had decided, in consultation with their physician, to either initiate PDE5 inhibitor treatment for the first time (treatment-naïve) or switch from any previous PDE5 inhibitor taken on-demand. Patients with previous experience with tadalafil OaD were excluded. The study was approved by the Comité de protection des personnes “Nord-Ouest IV”, centre hospitalier universitaire, tadalafil over the counter uk faculté de médecine, pôle recherche, 59045 Lille Cedex, and additional ethical review boards as per individual study site and country requirements (full list provided as Additional file 1). Patients provided written informed consent for data collection, storage, and release of anonymised data. Assessment and treatment of patients were performed as per routine investigator practice for managing ED. In this article, data from patients who initiated or switched to treatment with tadalafil OaD at baseline (Visit 1) and were followed up longitudinally for up to 6 months (tadalafil OaD cohort) are reported. Post-baseline data were collected at routine visits (Visit 2, Visit 3) within 1 to 3 months and 4 to 6 months after initiation of therapy. Patients who switched or discontinued tadalafil OaD treatment during the observation were followed until the end of the 6-month observation period. A follow-up phone call was made to patients who did not visit within 4 to 6 months after baseline.

In case of emergency/overdose

All patients prescribed tadalafil OaD treatment at baseline were included in the analysis. The primary results on the time to treatment discontinuation of tadalafil OaD in men who had initiated or switched to tadalafil OaD at baseline have already been published [20]. The current article includes secondary outcome results on the impact of patients characteristics and comorbidities on time to treatment discontinuation, and on mean changes from baseline to end of observation in the International Index of Erectile Function (IIEF) domain scores [21], and Erectile Dysfunction Inventory for Treatment Satisfaction (EDITS) total score [22]. A sample size of 250 patients initiating or switching to tadalafil OaD at baseline was planned, based on the primary outcome (continuation rate on tadalafil OaD, estimated to be 50 − 80 % after 6 months of treatment) [20]. Consecutive enrollment was planned to be stopped as soon as either 3,000 patients were enrolled overall, or 600 patients were enrolled in the tadalafil OaD cohort. All patients prescribed tadalafil OaD treatment at baseline were included in the analysis.

Site Operator

Fabienne Heyne
[email protected]

Corporate Design

Silvio Ketterer Visuelle Gestaltung
www.silvioketterer.ch

Website Programming

RHOdesign
www.rhodesign.ch

Photography

Angelika Annen
www.angelikaannen.ch